We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+59.82%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.55B
AUM Growth
+$107M
Cap. Flow
-$252M
Cap. Flow %
-16.27%
Top 10 Hldgs %
49.99%
Holding
236
New
61
Increased
26
Reduced
57
Closed
43

Top Buys

Rank Stock Value
1
KDMN
Kadmon Holdings, Inc.
KDMN
+$20.1M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$17.8M
3
RDUS
Radius Health, Inc.
RDUS
+$15.9M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$14.4M
5
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$13.6M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$45.8M
2
TSRO
TESARO, Inc.
TSRO
+$43.1M
3
NVRO
NEVRO CORP.
NVRO
+$31.9M
4
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$25.3M
5
STJ
St Jude Medical
STJ
+$18.2M

Sector Composition

Rank Sector Weight
1 Healthcare 91.49%
2 Technology 0.1%
3 Consumer Discretionary 0.07%
4 Industrials 0.07%
5 Consumer Staples 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
1
Sarepta Therapeutics
SRPT
$1.65B
$209M 13.46%
3,395,236
-372,080
-10% -$11.2M
NBIX icon
2
Neurocrine Biosciences
NBIX
$18.2B
$125M 8.09%
2,476,272
-321,695
-11% -$16M
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
$104M 6.74%
14,116,644
-1,122,800
-7% -$7.58M
TSRO
4
DELISTED
TESARO, Inc.
TSRO
$68.4M 4.42%
682,415
-461,200
-40% -$43.1M
TVTX icon
5
Travere Therapeutics
TVTX
$5.13B
$54.8M 3.53%
2,446,482
-832,898
-25% -$15.9M
GBT
6
DELISTED
Global Blood Therapeutics, Inc.
GBT
$53.8M 3.47%
2,334,168
+126,500
+6% +$2.41M
ARAV
7
DELISTED
Aravive, Inc. Common Stock
ARAV
$49.4M 3.19%
671,448
+198,822
+42% +$14.4M
NXTM
8
DELISTED
NxStage Medical Inc.
NXTM
$41.7M 2.69%
1,669,703
+287,293
+21% +$6.7M
XNCR icon
9
Xencor
XNCR
$1.44B
$36.6M 2.37%
1,496,229
-33,345
-2% -$705K
LJPC
10
DELISTED
La Jolla Pharmaceutical Company
LJPC
$31.5M 2.03%
1,323,324
-9,491
-0.7% -$179K
IOVA icon
11
Iovance Biotherapeutics
IOVA
$2.02B
$29.4M 1.9%
3,567,553
-44,423
-1% -$376K
WVE icon
12
Wave Life Sciences
WVE
$1.09B
$22.2M 1.43%
683,448
+160,853
+31% +$3.8M
XLRN
13
DELISTED
Acceleron Pharma
XLRN
$21.3M 1.38%
589,890
-13,146
-2% -$435K
CLCD
14
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$21.1M 1.36%
+552,030
New +$8.16M
TLPH icon
15
Talphera
TLPH
$67M
$21M 1.36%
270,436
-29,352
-10% -$1.95M
QTNT
16
DELISTED
Quotient Limited Ordinary Shares
QTNT
$20.9M 1.35%
66,795
+10,568
+19% +$2.97M
DBVT
17
DBV Technologies
DBVT
$801M
$20.5M 1.32%
56,327
+1,657
+3% +$576K
CRBP icon
18
Corbus Pharmaceuticals
CRBP
$167M
$18.3M 1.18%
90,034
-16,633
-16% -$2.07M
RGNX icon
19
Regenxbio
RGNX
$611M
$18M 1.16%
1,282,286
+183,073
+17% +$2.02M
RDUS
20
DELISTED
Radius Health, Inc.
RDUS
$17M 1.09%
+313,502
New +$15.9M
AVDL
21
DELISTED
Avadel Pharmaceuticals
AVDL
$16.9M 1.09%
+1,363,711
New +$17.8M
KDMN
22
DELISTED
Kadmon Holdings, Inc.
KDMN
$16.2M 1.05%
+2,209,657
New +$20.1M
DXCM icon
23
DexCom
DXCM
$29.3B
$15.7M 1.01%
715,396
+214,700
+43% +$4.78M
AERI
24
DELISTED
Aerie Pharmaceuticals
AERI
$15.4M 0.99%
+406,771
New +$8.97M
ALDX icon
25
Aldeyra Therapeutics
ALDX
$95.3M
$15.2M 0.98%
1,940,458
– –
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2016 Portfolio in Review

As of Q3 2016, Perceptive Advisors held 236 positions worth $1.55B, up 7.4% from $1.44B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors withdrew a net $252M in Q3 2016, closing 43 positions and reducing 57 holdings. Its most notable exit was MEDIVATION, INC., an estimated $45.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 76% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Perceptive Advisors opened a new position in Kadmon Holdings, Inc. worth $16.2M.

  • Perceptive Advisors's largest Q3 2016 buy was Kadmon Holdings, Inc.: 2,209,657 shares worth $16.2M.
  • Perceptive Advisors added most to Aravive, Inc. Common Stock in Q3 2016, an estimated $14.4M increase.
  • Perceptive Advisors's biggest Q3 2016 reduction was TESARO, Inc., cutting an estimated $43.1M.
  • Perceptive Advisors fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $45.8M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.55B portfolio in Q3 2016.
  • Perceptive Advisors opened 61 new positions and closed 43 in Q3 2016.
  • Perceptive Advisors's portfolio value rose 7.4% quarter-over-quarter to $1.55B.

Based on Perceptive Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.